How Investors May Respond To Amgen (AMGN) Repatha Expansion and 2026 Dividend Declaration

Simply Wall St.07-31 11:26

Amgen recently announced that its Board of Directors declared a US$2.52 per share dividend for the third quarter of 2026, payable on September 11, 2026 to shareholders of record as of August 21, 2026....

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2655168336?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/company-cover/24816-main-header/1756203123218","is_english":true,"pubTime":"2026-07-31 11:26","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2655168336","market":"hk","top_or_hot":-1,"title":"How Investors May Respond To Amgen (AMGN) Repatha Expansion and 2026 Dividend Declaration","media":"Simply Wall St.","content":"<div>\n<p>Amgen recently announced that its Board of Directors declared a US$2.52 per share dividend for the third quarter of 2026, payable on September 11, 2026 to shareholders of record as of August 21, 2026....</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-amgn/amgen/news/how-investors-may-respond-to-amgen-amgn-repatha-expansion-an\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>How Investors May Respond To Amgen (AMGN) Repatha Expansion and 2026 Dividend Declaration</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHow Investors May Respond To Amgen (AMGN) Repatha Expansion and 2026 Dividend Declaration\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-07-31 11:26 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-amgn/amgen/news/how-investors-may-respond-to-amgen-amgn-repatha-expansion-an><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Amgen recently announced that its Board of Directors declared a US$2.52 per share dividend for the third quarter of 2026, payable on September 11, 2026 to shareholders of record as of August 21, 2026....</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-amgn/amgen/news/how-investors-may-respond-to-amgen-amgn-repatha-expansion-an\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ISBC","symbol_name":"投资者银行","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-amgn/amgen/news/how-investors-may-respond-to-amgen-amgn-repatha-expansion-an","article_id":"2655168336","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/company-cover/24816-main-header/1756203123218"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-amgn/amgen/news/how-investors-may-respond-to-amgen-amgn-repatha-expansion-an","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2655168336","pubTimestamp":1785468363,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Amgen recently announced that its Board of Directors declared a US$2.52 per share dividend for the third quarter of 2026, payable on September 11, 2026 to shareholders of record as of August 21, 2026.\nSeparately, the European Medicines Agency’s CHMP issued a positive opinion on expanding Repatha’s use to high‑risk adults without prior heart attack or stroke, potentially broadening its clinical role in cardiovascular prevention.\nWe’ll now explore how the CHMP’s positive opinion on expanding...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"ISBC":"投资者银行","LU1023059063.AUD":"BGF WORLD HEALTHSCIENCE \"A2\" (AUDHDG) ACC","IE00BJJMRZ35.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (SGDHDG) ACC","LU1061106388.HKD":"BGF WORLD HEALTHSCIENCE \"A2\" (HKDHDG) ACC","IE00BFTCPJ56.SGD":"Janus Henderson Global Life Sciences A Acc SGD","IE00B4R5TH58.HKD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (HKD) ACC","BK4585":"ETF&股票定投概念","BK4534":"瑞士信贷持仓","TBXU":"Direxion Daily Biotech Top 5 Bull 2X ETF","LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD","BK4139":"生物科技","BK4533":"AQR资本管理(全球第二大对冲基金)","LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)","LU0122379950.USD":"贝莱德世界健康科学A2","LU1983299246.USD":"SCHRODER ISF HEALTHCARE INNOVATION \"A\" (USD) ACC","BK4566":"资本集团","LU0868494617.USD":"UBS (LUX) EQUITY SICAV - US TOTAL YIELD SUSTAINABLE \"P\" (USD) ACC","BIB":"Ultra纳斯达克生物科","LU0889565916.HKD":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC","AMGN":"安进","IBB":"生物科技指数ETF-iShares Nasdaq","LU0058720904.USD":"联博国际健康护理基金A","LU2242646821.SGD":"Fidelity Global Dividend Plus A-MINCOME(G)-SGD","BBH":"VanEck Biotech ETF","IE0009355771.USD":"骏利亨德森环球生命科技A Acc","LU2468319806.SGD":"MANULIFE GF HEALTHCARE \"AA\" (SGDHDG) ACC","SG9999001440.SGD":"United Global Dividend Equity Fund A SGD Dist","BK4588":"碎股","IBBQ":"Invesco Nasdaq Biotechnology ETF","LU1057294990.SGD":"Blackrock World Healthscience A2 SGD-H","LU1571399168.USD":"ALLSPRING GLOBAL LONG/SHORT EQUITY \"IP\" (USD) ACC","LU2242652126.USD":"FIDELITY FUNDS GLOBAL DIVIDENDS PLUS \"A\" (USD) INC","IE00B2B36J28.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I1\" (USD) INC","LU0289739699.SGD":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC","PJP":"INVESCO PHARMACEUTICALS ETF","PBE":"INVESCO BIOTECHNOLOGY & GENOME ETF","IE00BJT1NW94.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (SGDHDG) ACC","BK4211":"区域性银行","LU2089984988.USD":"MANULIFE GF HEALTHCARE \"AA\" (USD) ACC","IE0002141913.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (USD) ACC","LU2112291526.USD":"BGF WORLD HEALTHSCIENCE \"A4\" (USD) INC","BK4581":"高盛持仓","BK4599":"减肥药"},"translate_title":"投资者如何应对安进 (AMGN) Repatha 扩张和 2026 年股息宣告","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"IBBQ":0.6,"BBH":0.6,"BIB":0.6,"ISBC":1.5,"AMGN":1.5,"TBXU":0.6,"IBB":0.6,"PJP":0.6,"PBE":0.6},"content_text":"Amgen recently announced that its Board of Directors declared a US$2.52 per share dividend for the third quarter of 2026, payable on September 11, 2026 to shareholders of record as of August 21, 2026. Separately, the European Medicines Agency’s CHMP issued a positive opinion on expanding Repatha’s use to high‑risk adults without prior heart attack or stroke, potentially broadening its clinical role in cardiovascular prevention. We’ll now explore how the CHMP’s positive opinion on expanding Repatha’s cardiovascular indication could influence Amgen’s broader investment narrative. Uncover the next big thing with 21 elite penny stocks that balance risk and reward.AdvertisementAmgen Investment Narrative RecapTo own Amgen, you need to believe its diversified drug portfolio and pipeline can sustain meaningful cash generation despite pricing pressure and biosimilar competition. Near term, the key catalyst is upcoming earnings and any updates on portfolio performance, while the biggest risk remains ongoing drug price pressure and loss of exclusivity in core franchises. The CHMP’s positive view on Repatha could be supportive, but it does not fundamentally change that central risk. Among recent developments, the reaffirmed US$2.52 per share dividend for Q3 2026 stands out as directly relevant. It underlines Amgen’s ongoing commitment to returning cash to shareholders at a time when investors are watching how increased R&D spending, manufacturing investment, and patent challenges will affect cash flows. That consistency may matter as the market weighs the potential impact of an expanded Repatha label alongside broader questions around pricing and competitive pressure. Yet against this steady dividend story, investors should still be aware of how intensifying global efforts to regulate and cap drug prices could... Read the full narrative on Amgen (it's free!)Amgen's narrative projects $40.1 billion revenue and $9.9 billion earnings by 2029.Uncover how Amgen's forecasts yield a $352.23 fair value, a 9% downside to its current price.Exploring Other PerspectivesAMGN 1-Year Stock Price Chart While the baseline view focuses on pricing pressure and biosimilars, the most optimistic analysts were already assuming about US$44.4 billion of revenue and US$13.2 billion of earnings by 2029, so this Repatha news could either reinforce or challenge those expectations depending on how you think the story evolves from here.Explore 5 other fair value estimates on Amgen - why the stock might be worth 9% less than the current price!The Verdict Is YoursDisagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.A great starting point for your Amgen research is our analysis highlighting 3 key rewards and 1 important warning sign that could impact your investment decision.Our free Amgen research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Amgen's overall financial health at a glance.Seeking Other Investments?Early movers are already taking notice. See the stocks they're targeting before they've flown the coop:AI is about to change healthcare. These 41 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.This technology could replace computers: discover 25 stocks that are working to make quantum computing a reality.Rare earth metals are an input to most high-tech devices, military and defence systems and electric vehicles. The global race is on to secure supply of these critical minerals. Beat the pack to uncover the 29 best rare earth metal stocks of the very few that mine this essential strategic resource.  This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: Manage All Your Stock Portfolios in One PlaceWe've created the ultimate portfolio companion for stock investors, and it's free.• Connect an unlimited number of Portfolios and see your total in one currency• Be alerted to new Warning Signs or Risks via email or mobile• Track the Fair Value of your stocksTry a Demo Portfolio for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.46.0","shortVersion":"4.46.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2655168336","isCrawlerRequest":true}